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ADC – Antibody-Drug Conjugate 
AR – Androgen Receptor 
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CRHC – Cancer-Related Health Cost 
DNA - Deoxyribonucleic acid 
EBV – Epstein-Barr virus 
EGFR – Epidermal Growth Factor Receptor 
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HER2 – Human Epidermal growth factor Receptor 2 
HHV-8 - Human Herpes virus 8 
HPV - Human Papillomaviruses 
IARC – International Agency for Research on Cancer 
mAb – Monoclonal Antibody 
MDM2 – Murine double minute two 
mTOR – Mammalian Target of Rampamycin 
PAMAM - Poly(amido)amine 
PEG – Polyethylene Glycol 
PR – Progesterone Receptor 
STAT3 - Signal Transducer and Activators of Transcription 3 
TNBC – Triple Negative Breast Cancer 







 O cancro da mama é uma doença responsável por milhões de mortes 
anualmente. É uma doença muito heterogenia devido às diferentes mutações 
existentes em cada caso. O cancro da mama não tem uma cura existente, ele é 
tratado através de uma série de esquemas terapêuticos que envolve 
radioterapia, quimioterapia e cirurgia. Tanto a radio como a quimioterapia são 
unicamente adjuvantes de modo a permitir a remoção do cancro através de uma 
lumpectomia ou mastectomia. A quimioterapia corrente usada não consegue 
distinguir células malignas de células saudáveis e isso remete para reações 
adversas sentidas pelo doente que tornam a terapia dolorosa. Existe, portanto, 
uma demanda de novas opções terapêuticas mais eficazes e seletivas. 
Contundo, muito investigadores referem descobrir novas terapêuticas seletivas 
que acabam por não o ser. Faz-se uma crítica a potenciais novos fármacos em 
investigação, mas também se propõe a síntese de fármacos mais eficazes e 
viáveis na cura do cancro da mama. 
Abstract 
 Breast cancer is a disease responsible for millions of deaths annually. It’s 
a very heterogenous disease due to the different mutations on each case. Breast 
cancer doesn’t have existing cure, and it’s currently approached through 
therapeutic schemes involving radiotherapy, chemotherapy and surgical 
procedure. Both radiotherapy as chemotherapy act adjunctly allowing further 
removal through lumpectomy or mastectomy. Current chemotherapy can’t 
distinguish between healthy and malignant cells, causing patient suffering 
through adverse effects. So, there’s a demand to find out novel therapies more 
efficient e selective. However, many researchers claim to found novel selective 
approaches, that ultimately aren’t. Potentially new drugs on research will be 






Cancer Statistics  
Worldwide 
According to the World Health Organization (WHO), cancer is the second 
leading cause of death globally, being responsible for 8.8 million deaths in 2015 
meaning that 1 in every 6 deaths is due to cancer (1). 
Only in 2012, approximately 14 million new cases were reported. This 
number is expected to rise about 70% over the next two decades representing a 
serious threat to global human life (1). 
The most common worldwide type of cancer, in 2012, was: lung, breast 
(women only), colorectal, prostate and stomach in decreasing order; and the 
number of new cases diagnosed (thousands): 1,825; 1,677; 1,361; 1,112; 952 
respectively (2). 
The total annual economic cost of cancer in 2010 was estimated nearly 
1.1 trillion euros, this value is expected to keep increasing (1). 
A study conceived by the American Cancer Society and LIVESTRONG 
organization, reported that in 2008 the total economic impact of cancer worldwide 
was $895 billion, being the most expending world cause of death. The value 
includes premature death and disability which accounts for productivity losses, 
representing 1.5% of gross domestic product (GDP). The study also shows that 
the top three most global economic impact cancers are lung ($188 billion), 
colorectal ($99 billion) and breast ($88 billion) (3). 
 
Europe 
The overall view in Europe alone is very similar and equally concerning. 
Cancer is also the second most important cause of death and morbidity in 
Europe, with about 1.9 million death cases each year, and more than 3.7 million 




Also, in 2012, the most common type of cancer in Europe in decreasing 
order was: breast (women only), colorectal, lung, prostate, bladder, and the 
respective values (thousands) : 463,8; 446,7; 416,7; 409,9; 151,2 (5). 
In 2009, a study evaluated the economic burden of cancer in the European 
Union reporting that over 126,205 billion euros are spent in cancer-related issues. 
This value covers both cancer-related health costs (CRHC) and productivity 
losses.  50,994 M € are spent only in CRHC and the expenditure with drugs 
accounted for 13,604 M € which represents more than a quarter of the value 
invested to overcome cancer. They’ve also shown that breast, prostate, 
colorectal and lung cancer were the highest CRHC, representing 43% of all 
cancer types (6). 
Since cancer carries a great impact in both health and economy all over 
the globe, understanding it’s prevention, occurrence, and state of the art 
therapies, grants the possibility of evaluate current barriers to optimal drug 
designs, allowing new drugs developments with higher efficiency, largely 
increasing the quality-adjusted life year (QALY) of the population or even by 
eliminating the disease; but also, educates the population to reducing risk 




 There are several theories which lead to today’s knowledge of cancer 
development.  
The cellular theory defends that the origin of cancer derives from a unique 
normal cell. Many researchers claim other discoveries and/or evidence that 
support this theory. One of which was from Weiberg in 1998 which claimed that 
the risk to contract cancer was 10% or 1 in 1015 based on the average human 
body cell divisions in a lifetime (1016). Another research by Hockenbery et al. 
1990 showed that transfecting normal B-lymphocytes with gene bcl-2, involved in 




malignant. These researches prove that to promote carcinogensis, there must be 
a gap in the cell growth control and also in the cell death prevention, on normal 
healthy cells (7). 
The noxious theory stands for exogenous damaging agents: chemicals, 
radiation and virus, that lead to tumorigenesis. This is the current theory that is 
easily correlated with nowadays worldwide cancer impact. Due to the 
overpopulation and the need to extract resources enough to achieve a healthy 
life-style for everyone, many strategies were adopted, an example of one is the 
use of pesticides to increase food quantity. The exposure to these chemicals 
have been already correlated with the development of carcinogenesis in the 
human body. One of the most common associations with chemicals and 
carcinogenesis, is the usage of tobacco, which has been greatly correlated with 
lung cancer by many researchers (8,9). Of its compounds, polycyclic aromatic 
hydrocarbons are the most proved to induce cancer, through DNA adducts 
formation, which damages DNA. If not repaired or if the cell doesn’t initiate 
apoptosis, the cell could replicate and lead to carcinogenesis (10,11). 
The International Agency for Research on Cancer (IARC) is an 
organization belonging to WHO, and for the past 30 years has been testing many 
chemicals that may induce carcinogenesis in the human body (12). 
Another noxious induced category is radiation. While the mechanisms 
underlying radiation promotion of carcinogenesis are not quite yet established, 
studies that followed the individuals exposed to gamma radiance from atomic 
bombs showed that they have higher chance of developing cancer rather than 
individuals not exposed to it (13–15). 
Besides atomic bombs, high sunlight exposure is correlated with 
nonmelanoma skin cancer development. UV radiation is divided by wavelength 
intervals into subgroups A, B and C. The UV-C is filtered in the atmosphere while 
A and B pass it. While there’s evidence correlating melanoma with UV-B 
radiation; UV-A is also starting to be considered cancerous after chronic exposure 
(16). 
UV radiation promotes, in the cell’s DNA, malignant dimer formation as the 




and can act by simple breaking single-strand DNA. These products will lead to 
carcinogenesis if not managed by the cell (17). 
The last category in the noxious theory are viruses. Several viruses can 
lead to cancer. 
Hepatitis B has been proved to develop hepatocellular carcinoma, 
although the mechanism in which occurs are not quite yet defined. There are 
multiples ways this virus could cause carcinogenesis:  through the inflammatory 
process as an immune response, which could inflict damage on the cellular DNA; 
integration of the virus genome into the hosts DNA; epigenetic modifications; or 
inducing oxidative stress (18–20). 
Human Papillomaviruses (HPV) consist in a double-stranded DNA that has 
tropism to epithelial cells. HPV induces cervical cancer in women, being the 
second most common cancer development in this gender. There are two risk 
types of HPV; high-risk viruses (type 16 and 18 for example) that act by 
integrating its own genome into the target cell genome, while the low-risk infect 
the cell leaving its genome as an episome. The former group is responsible for 
70% of the cervical cancers. Although the carcinogenesis induction mechanism 
is correlated with E6/E7 HPV genes expression levels, without other external viral 
factors (e.g. a low estrogen concentration) there’s no progression in cervical 
cancer (21–24). 
Carcinogenesis induced by Epstein-Barr virus (EBV) is associated with T 
and B lymphomas, Hodgkin’s disease and nasopharyngeal carcinoma (25,26). 
Although the association between the virus and the malignant pathologies have 
been studied, there’s not yet evidence revealing how does the virus induces 
tumorigenesis in different types of cells (27). 
The somatic theory attributes carcinogenesis to chromosomal disorder. A 
major hallmark in this theory was the discovery of the Philadelphia chromosome 
in chronic myeloid leukaemia, resulting in a reciprocal translocation between of 
chromosome 22 and 9. The abnormal protein generated, stimulated the 




Another evidence supporting the somatic theory are aneuploidies, higher 
or lower changes in the DNA quantity. It’s reported that higher changes are more 
often associated to tumorigenesis (29,30). 
In all the previous theories, a common characteristic is shared. The 
disturbance of the human cell genome is present in all tumorigenesis-mechanism 
induction theories. Having this evidence, it’s important to understand how the 
human body naturally responds to prevent the evolution of a damaged cell into a 
tumour. 
DNA repair mechanisms  
When treating an existing tumour, many cytotoxic drugs act by targeting 
the DNA and induce mutations to lead the malignant cell to death. However, some 
endogenous repair mechanisms activate to prevent the cytotoxic effect. The 
repairing mechanisms could also be a future target for new to come cancer-
reduction or cancer-elimination therapies. 
Table 1 – Endogenous repair mechanism according to a certain lesion type and the respective compounds 
in study to target them. 
Repair Mechanism Lesion Type Inhibitors compound in 
study 
Base Excision Repair (BER) Oxidative lesions ML-199 
NCS-666715, AR03 
Non-homologous end joining 
(NHEJ) 
Double-strand breaks CC-115, CC-122, 
A12B4C3 
Mismatch repair (MMR) Nucleotide mismatch, 
Deletion loops 
Polβ inhibitor in MSH2-
deficient cells, 
Methotrexate 
Single strand break repair 
(SSBR) 
Single strand breaks Olaparib, Iniparib 
Homologous Recombination 
(HR) 
Double strand breaks Mirin, RI-1 
Nucleotide Excision Repair 
(NER) 
Double strand breaks UCN-01, Trabectedim 
DNA interstrand crosslink 
repair pathway 





Table 1 briefly shows DNA repair mechanisms, specialized into different 
types of DNA lesions. These mechanisms are suspected to increase chemo and 
radiotherapy resistance in cancer therapies. To increase therapy success, DNA 
repair inhibitors are being tested as adjuvant in DNA-damage cancer therapies 
(31–35). 
Tumor promotion 
In normal healthy cells, the previous DNA repairing mechanisms act by 
keeping the cell intact to harmful exogenous compounds, capable of inducing 
malignant transformation. However, there is still a great percentage of people that 
at some point develop cancer. If these repairing mechanisms fail, the cell notices 
an abnormality, signals itself and triggers an apoptosis state to prevent turning 
malignant. So how can cancer development happen? 
A genetic approach explains how a mutation can lead to a tumour that 
keeps growing, mostly due to the disturbance on two gene classes: oncogenes 
and tumour suppression genes. 
Oncogenes are dominant genes that encode proteins that are responsible 
for cell proliferation and for the regulation of the apoptosis pathway. Oncogenes 
are derived from protooncogenes when the later suffers structural alterations 
(mutation, gene fusion, juxtaposition to enhancer elements, amplification). Since 
protooncogenes are also dominant, it means they only have one allele needed to 
be targeted to promote tumour progression, which makes it easier to turn a 
normal cell into a malignant one. One oncogene example is the epidermal growth 
factor receptor (EGFR) gene that is expressed in several squamous carcinomas 
(head, neck, lung, etc…). EGFR is a receptor that’s part of the tyrosine kinase 
family. Its activation induces signalling transduction cascades like 
RAS/RAF/MAPK pathway and PI3K/AKT pathway that allows cell proliferation 
and cell survival(36). Due to the EGFR pathway role in certain tumour 
proliferation, many cancer therapies have been developed to target it (37,38). 
Tumour suppression genes counters the action of oncogenes, by 
intercepting the tumour progression pathway to stop cell proliferation. They are 




function, adding an additional barrier on cancer prevention.  An example of a 
tumour suppression gene class is the protein p53. The p53 levels are maintained 
low due to a ubiquitin ligase murine double minute two (MDM2), which is activated 
in the presence of high p53 levels. This protein is expressed due to some 
stressing cellular environment, causing the arrestment of the cell-cycle, leading 
to apoptosis or senescence. Due to the MDM2-p53 signal relevance in regulation 
of cell-cycle (39), these molecules are also another cancer therapy target (40,41). 
Since an overbroad explanation about carcinogenesis process has been 
introduced, and the worldwide social and economic impact of breast cancer has 
also been demonstrated, it’s important to understand the cellular malfunctions 
that lead to breast cancer and the current therapies aimed to treat this disease. 
Breast Cancer 
As demonstrated before, this pathology affects largely more women than 
men, therefore, this subject will be focused on the female gender only. 
Breast Cancer Subtyping 
Breast cancer (BC) is a very heterogenous disease. However, by 
analysing each case, it was concluded that some malignant cells share 
similarities amongst themselves, allowing a division according to their molecular 
portraits or gene expression, without compromising the diagnostic accuracy. Due 
to the purpose of this thesis, five main subtypes will be briefly discussed 
according to their molecular portraits: Luminal A, Luminal B, HER2-enriched, 
Basal-like and Claudin-low (42). 
Luminal A and B subtypes received their name following the similarity in 
the gene expression on the luminal epithelium breast cells. They are 
distinguished from the other subtypes by analysing the high expressed levels of 
estrogen receptor (ER), which was found to be equal among them, and 
progesterone receptor (PR) levels, being lower in luminal B subtype (42,43). 
Luminal A subtype, contrary to the luminal B, has an upregulated expression of 
genes involved in cell differentiation and cell adhesion (eg. Jun proto-oncogene). 




(eg. Cyclin B1), found as downregulated in subtype A, and activation of growth 
factor receptor signalling pathways  as IGF-1R PI3K/AKT/mTOR,  which explains 
it’s faster levels of proliferation (44). On the DNA level luminal A shown an overall 
lower mutation number than luminal B subtype (42).  
HER2 - enriched Human Epidermal growth factor Receptor 2 (HER2) – 
enriched subtype has high expression levels of genes and proteins related to the 
HER2 and cell proliferation (eg, ERBB2, GRB7), low expression of basal-like-
related genes and proteins (eg, FOX1, keratin 5) and normal levels of luminal 
genes (ESR1 and PGR) (42). HER2-enriched also presents high levels of 
receptor tyrosine kinase genes like FGFR4 and EGFR both responsible for cell 
proliferation and differentiation (37,45,46). HER-2 is the subtype with the most 
mutations across the genome. 
 Basal-like subtype, is characterized at the RNA and protein expression, 
with high levels of proliferation-related genes (eg. MKI67) and keratins which are 
found in the basal layer of the skin with low expression of luminal-related genes, 
and moderate expression of HER2-enriched-related genes. This subtype is the 
second with most abnormalities in the genome (42). Basal-like subtype it’s often 
referred as Triple Negative Breast Cancer (TNBC), due to the negative values of 
ER, PGR and HER2 by immunohistochemical staining, but not all TNBC have the 
molecular portrait discussed in Basal-Like subtypes (47,48). 
 Besides intrinsic molecular classification, expression of ER, PGR, and 
HER2 has been used to group BC patterns. The below image helps understand 
the correlation between intrinsic molecular and gene expression subtyping of BC. 
 
Figure 1- Correlation between Molecular portrait (Intrinsic subtype) classification and 
immunohistochemical staining calssification of ER, PR and HER2. Adapted from Intrinsic Subtype 
and gene expression correlation disclaimed in the St Gallen International Expert Consensus of the 




 Although all the above subtypes have been classified and studied for 
decades, only in 2007 a new molecular subtype was found, called Claudin-low. 
This subtype is characterized by the low gene expression of claudins, and E-
cadherin, both responsible for tight junctions in epithelial or endothelial cells. 
Claudin-low subtype showed irregular expression of keratins and low expression 
genes regarding HER2-enriched, Luminal A and B subtypes, meaning they also 
share the phenotype of TNBC. Conversely, Claudin-low revealed high expression 
levels of genes related to: immune response, cell communication, cell migration, 
cell differentiation, extracellular matrix and angiogenesis (49). 
Breast Cancer Subtypes Prognosis 
To prioritize and define new BC drugs, and due to the large heterogeneity 
of this disease, there’s a need to evaluate patients’ outcome. Although age and 
tumour nodes are important to evaluate patients’ prognosis, the focus will be kept 
of the cancer subtypes. 
 
Figure 2 – Kaplan-meier plot of Overall Survival of local, unilateral non-metastatic breast cancer subtypes 
according to their molecular portrait and the corresponding survival time, measured in months after a 
lumpectomy or a mastectomy. Adapted from Hennings A, Riedel F, Gondos A, Sinn P, Schirmacher P, 
Marmé F, et al. Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective 
cohort study.  
Observing the first image (Fig.2), a Kaplan-Meier plot compares the 
survival probability to the intrinsic subtype of BC in a two and half year period, 
after a lumpectomy or a mastectomy. As the results show, Luminal A has the 
best survival probability score and triple-negative has the lowest one. Since the 
results are from a prospective cohort study, with defined endpoints, the data 





Table 2 - Multivariable Cox proportional hazards analyses for 5-year post-recurrence on breast cancer 
mortality. Adapted from Kimbung S, Kovács A, Danielsson A, Bendahl P-O, Lovgren K, Stolt MF, et al. 
Contrasting breast cancer molecular subtypes across serial tumor progression stages: biological and 
prognostic implications. 
Biomarker status of primary tumours N Relative hazard 
ER 275  
Positive (reference) 210 1.0 
Negative 65 2.2 
PR 259  
Positive (Reference) 149 1.0 
Negative 110 1.5 
Intrinsic Subtype 175  
Luminal A (reference) 64 1.0 
Luminal B vs Luminal A 81 1.3 
HER2-enriched vs Luminal A 8 2.5 
Triple Negative vs Luminal A 23 3.1 
 
The table 2 represents the mortality in a five-year post-recurrence of BC 
according to gene expression subtype and intrinsic molecular subtype, defining 
the value as hazard ratios. As shown, patients with both ER and PR negative 
values were more likely to die. Also, the intrinsic subtypes were rated in 
accordance with the previous image, showing again, that the triple-negative 
phenotype has the worst prognosis. These values were adjusted for adjuvant 
endocrine or chemotherapy treatment, node status and age (51). 
The above subject referred only to the prognostic value concerning 
primary tumours. It’s important to understand that cancer can develop metastasis 
that will change the prognostic value and the therapy selected to the patient. Due 
to its relevance in patient outcome, it is necessary to discuss how metastasis 
develops and what are the consequences for the patients. 
Breast Cancer Metastasis 
 In every cancer, that is not removed or treated, there’s always a chance 
that cells from a primary local tumour will migrate, through blood or lymph 




This process is called metastasis. Due to the metastasis brutal invasive 
characteristic, current treatment isn’t able to cure it. As for now, it can only stop 
its expansion, possibly leading to its elimination for a short period of time. Since 
recurrence probability stays high after tumour elimination, pharmaceutical 
companies are trying to develop better treatments that can lead to an increased 
length of time without new recurrences. 
 As the primary tumour gets access to the blood vessels, more possible 
sites become available within the body for new tumour cells to adhere. It’s not yet 
explained why, for each type of tumour, there are some preferable sites than 
others. In breast cancer, a study recorded which sites were more targeted by 
metastasis in a small population sample (52). According to the figure 3, the most 
prevalent sites for BC metastasis are bone, lung and liver. It’s important to notice 
that the image does not represent the first metastatic site and does not adjust the 
value for how many metastasis sites where before a new one shows up, it only 
shows the frequency on certain body organs. So how does the tumour forms 
metastasis? 
Briefly, after the first appearance of a single cancer cell, due to its 
expression of molecules promoting proliferation and differentiation, it starts 
growing and multiplying faster than the surrounding healthy cells. Since this new 
tissue expands faster, it eventually reaches blood or lymphatic vessels and 
intravasates into them. On the blood stream, after evading the immune system 
they will adhere to capillary beds, followed by the extravasation into target tissue, 
and start to proliferate and induce angiogenesis. In this new site, just like the 
Figure 3 – The most common organs for a metastasis of breast cancer. 
Adapted from Weigelt B, Peterse Johannes L. Veer Laura J. Breast Cancer 




other, can now repeat the process, originating a second source of the metastasis 
(53). The detailed mechanisms of metastasis are complex and involve: cell to 
extracellular matrix and cell-to-cell adherence proteins alterations, morphologic 
changes, from epithelial to mesenchymal to promote cell migration and 
expression of angiogenic proteins (52). These steps are not furthered described 
since they’re not essential for this thesis, however, they are critical to the 
successfulness of tumour metastasis and could become future targets for cancer 
treatment and so are worth mention.  
 As the prognostis of a metastasis-state cancer deeply worsens comparing 
to a local confined primary tumour, it’s important to monitor as earlier as possible 
the induction of metastasis in order to increase the successfulness of the therapy.  
 The detection of early markers can increase the therapy efficiency through 
quicker elimination of metastasis. Many markers detect cancer cells within the 
blood, which can be very helpful because the tumour cell possibly hasn’t adhered 
to a tissue target and hasn’t also started to produce more cells that can lead to 
secondary metastasis. In association with early detection, quicker and less 
patient-invasive methods could increase the monitoring of the disease, also 
contributing to resolve the pathology.  
 Several markers are used to identify BC blood disseminated cells, which 
have great sensibility but lack specificity. No marker is exclusive of breast cancer 
disease, because it was also found in healthy individuals. However, some 
markers have been reported to be more specific in detection of breast cancer 
disseminated cells than others: 
SCGB2A2 - Also known as mammaglobin, may be involved in signalling 
the immune response. Because it’s not expressed on a variety of breast cancer 
subtypes, this protein has a limited use. SCGB2A1 and SCGB1D2 are other 
isoforms also used in detection, that have equivalent expression levels to 
SCGB2A2 (54). 
PIP – Prolactin-inducible protein or gross cystic fluid protein-15, is specific 
and sensitive to apocrine differentiation, and its levels are correlated with ER and 
PGR levels (55). Although in low levels, PIP was found in other tissues, making 




TFF1 and TFF3 – Trefoil factor 1 and 3 are small cystine-rich proteins 
containing one trefoil domain with 6 cystines, linked by 3 disulphide bridges. 
These proteins are involved in the protection and regeneration of the luminal 
mucosa, preventing inflammation and beneficing cancer development. Estrogens 
increases the expression of these proteins, meaning they’re markers for ER-
positive breast cancer.  Despite being specific, TFF1 and 3 are present in 65% of 
all breast cancer, limiting its prediction value (54). 
SPDEF – SAM Pointed Domain containing Ets transcription Factor is a 
protein belonging to the ETs-domain family, whose expression deregulation, is 
associated with certain types of cancer (56). It’s exclusively found in high 
epithelial tissues such as breast and prostate. 
These are several other markers (54) used in single or multi-markers 
assays to detect breast cancer cells on the blood with different specific and 
sensibility degrees. 
Breast Cancer Metastasis Prognosis 
As previously mention, a metastatic cancer has a severely worse 
prognosis, due to the invasiveness and the corresponding tissue damage in the 
organs affected. Relapse-free period and the different metastatic sites are crucial 
factors for evaluating the prognosis. A cohort study (57) with 797 patients was 
conducted, showing the overall survival correlated with the gene expression 
subtypes. Triple-negative subtype shows, again, the worse scenario with a 
Figure 4 - Survival after diagnostic of a metastatic breast cancer according to the status of hormone 
receptor and HER2. Adapted from Lobbezoo DJA, van Kampen RJW, Voogd AC, Dercksen MW, van den 
Berkmortel F, Smilde TJ, et al. Prognosis of metastatic breast cancer subtypes: the hormone 




medium survival value of 8.8 months, while HR+/HER2+ (Luminal B) shows the 
best prognosis, with a medium survival value of 34.4 months.  
 Compared to the primary tumour we can observe a marked decree in the 
survival months after the diagnosis. This represents a bigger urgency in finding 
better treatments to target metastatic BC. 
Treatment   
After a broad view of BC, it’s important to understand the standard 
procedures currently used to treat it, in order to further discuss about targeted 
cancer therapies. 
As mentioned, BC is very heterogenic, with different genes and proteins 
expressed on almost each new case, which makes it harder to have a unique and 
precise therapy that could overcome it. Besides, the treatment varies according 
the tumour stage (see Annexes).  
On early stages, the patient submits to a lumpectomy, where the solid 
tumour plus the surrounding tissue will be removed, and might be followed up 
with radiotherapy, using x or γ-rays to damage the DNA of cancer cells, leading 
to apoptosis (58). Another option is to perform a mastectomy, removing all the 
affected breast. 
On further stages, chemotherapy is added according to its phenotype (ER, 
PR and HER2 status), presence/absence of recurrences and/or metastasis. In 
chemotherapy, the approach to kill cancer cells is achieved with cytotoxic drugs 
that target: nucleic acids, DNA/RNA production, and cell cycle process. The 
general clinical use of chemotherapy is to shrink tumour size and to inhibit tumour 
growth so it can be further removed through surgery. In advance stages, 
chemotherapy will only sustain the patient’s life for a short period of time. 
These are some of the most used cytotoxic drugs in BC therapy. They can 
be single-used or mixed in combination, for increasing adjuvant results. 
Parameters like duration and amount, are deducted in each cancer case 




   
 Most of the drugs lack BC selectivity. This leads to adverse effects 
manifested by the patients receiving the treatment. Besides the psychological 
burden, vomiting, nausea and hair loss are also a part of the therapy regime 
downside. Yet, after concluding the therapy, recurrences might appear, forcing 
the patient to do more procedures or, if the therapy fails, it will, ultimately, lead to 
death. 
 There’s a worldwide need to find new markers and/or new drugs that can 
target BC cells exclusively, first suppressing cancer growth and then eliminating 
the malignant cells.  
  
Cytotoxic Drug Mechanism of action 
Anastrozole/letrozole/exemestane Inhibitor of aromatase enzyme. 
Capecitabine/Fluorouracil Inhibitor of thymine synthesis, breaking cell 
replication. 
Carboplatin/Cyclophosphamide Alkylates DNA forming adducts through crosslinks, 
blocking DNA replication or transcription. 
Docetaxel/Paclitaxel Binds to tubulin, perturbing the microtubule 
assembly and stopping cell cycle in G2/M phase.  
Doxorubicin Disturbs the DNA, inhibiting topoisomerase II. 
Everolimus mTOR inhibitor. 
Lapatinib Inhibitor of EGFR and of HER2 receptors 
Methotrexate Inhibitor of dihydrofolate reductase, stopping DNA 
synthesis. 
Trastuzumab/Pertuzumab Binds to the extracellular domain of the HER2 





Review and discuss Targeted Therapies in Breast Cancer and comparing with 
current therapy. 
 
Materials and Methods 
To obtain information on targeted therapies in BC the following databases 
we’re used: B-on, PubMed (on Best Match mode), Google Scholar, Nature, Cell 
and Clinical Oncology Journals. 
To select the results, the following exclusion criteria were applied: older 
than 2007, exclusive detection studies, exclusive imaging applications. Inclusion 
criteria: perspective, novel, selective, in vivo. Only those who were accessible 
were used for discussion and only the top 25 matches were selected. 
Concepts used: Novel/New, Targeted, Selective, Drugs, Breast Cancer. 
 
Results 







 From the above cytotoxic drugs currently used in BC therapy, a common 
characteristic stands out: none of these drugs are anti-BC designed. Although 
they have clinical value, they’re only successful if the cancer is detected in an 
early stage, and it still must be further removed through a lumpectomy.   
 Some of the drugs act by inhibiting DNA synthesis, microtubule assembly 
and topoisomerase II. Even if it’s administrated in a local-region, bypassing the 
blood circulation, the drug itself can’t distinguish between malignant and normal 
cells, because these inhibitory mechanisms are also present in all cells. So, by 
killing healthy cells, besides failing the therapy purpose, adverse effects will likely 
occur. 
 Non-DNA targeted drugs aren’t also BC specific. Lapatinib and 
trastuzumab act by binding to the HER2 receptor. HER2 (ErbB-2) receptor 
belongs to the human epidermal growth factor family, which is overexpressed in 
20-30% of breast cancers (59). An overexpression is simply an abnormally high 
level of synthesis compared to the normal basal levels. This means that healthy 
cells also express this receptor, just not in large amounts as found in BC cells. 
Therefore, although these drugs will bind more often to cancer cells, they will also 
bind to normal cells, creating a lack in cancer cell selectivity. Lapatinib additionally 
binds to EGFR (ErbB-1) which is another receptor from the same family as HER2 
and equally expressed in other organs, facing the same selective problem. 
 Everolimus acts by inhibiting the mammalian target of rapamycin (mTOR), 
which is a serine/threonine kinase belonging to the phosphoinositide kinase-
related family of protein kinases (PIKK). It coordinates several cellular functions 
as survival, proliferation and differentiation (60). Mutations in the mTOR pathway 
have been found in increased levels in ER positive BC. These mutations allow an 
increment level of mTOR, which is associated with resistance to endocrine 
therapy. Everolimus can be combined with exemestane to increase clinical 
outcome (61). However, this approach lacks selectivity between normal and 





 Before analysing novel therapies in study, it’s important to refer why some 
therapies fail to be more efficient on current clinical practices. Cancer cells can 
avoid being targeted by the human’s immune response system, and by cytotoxic 
drugs. Regarding the immune response system, once T-cell recognises tumour 
cells, they release interferons through their T-cell receptor, which will boost the 
immune response by recruiting other leukocytes. One theory suggest that the 
malignant cell activates an interferon-inducible immune suppressive factors, 
limiting the immune response system and increasing tumour ability to survive. 
Another theory, only tested in mouse models, suggests that in the presence of T-
cell pro-inflammatory cytokines, tumour cells changes its phenotype, reducing the 
expression of differentiated antigens, and assuming a less-differentiated state, 
thus avoiding the immune response system (62). 
 Cancer cells have different ways of resisting to a cytotoxic drug: 1) by 
changing the target from which the cytotoxic drug was designed. These changes 
usually involve mutations, lowering the binding between the drug and the target. 
This brings opportunity to develop further generations of cytotoxic drug that will 
target the altered phenotype. 2) upstream or downstream reactivation of target 
pathway. This resistance mechanism was found in anti-HER2 BC therapy with 
trastuzumab or lapatinib, through changes in the activation of the PI3K pathway, 
which, in turn, signals downstream of HER2. 3) drug-dependent survival. The 
malignant cell re-writes certain pathways signalling survival that become drug-
dependent, meaning that they will only be active in the presence of the drug. In 
some cases, with the withdrawal of the cytotoxic drug, the pathway turns inactive, 
and the cell dies. [4] through cross-talk activation of similar pathways. When 
inhibiting, for example, the MAPK pathway, that leads to tumour survival, studies 
found that a similar pathway, PI3K, that also lead to tumour survival, was 
activated, suggesting a cross-talk between these signalling pathways upon 
internalization of cytotoxic drug.(63) 
 Understanding tumour-resistance development will help in developing 






 Results found are grouped according to drug class, allowing a brief 
explanation of the pharmacokinetics proprieties and difficulties to overcome in 
target drug-delivery of each group.   
Small-Molecules 
 Administration of small-molecules may be the most difficult approach of 
developing efficient therapies. To design them, one must consider all the barriers 
facing drug delivery. The most important one, obligates the molecule to be stable 
in an aqueous solvent, around pH levels of 7.35-7.45, which are the physiological 
conditions, otherwise it will react and possibly lose its functional moiety. Other 
barriers such has drug absorption, distribuition, metabolism, and excretion, may 
be avoided through an appropriate administration route choice.  
 Small-molecules are the generic drug type, and despite novel drug 
innovations, such as the creation of biosimilars, there’s still an ongoing-search 
for novel small-molecules as a therapeutic agent.  
 A review (64), lists pharmaceuticals’ small-molecules on clinical trials to be 
proven efficient in metastatic BC. These drugs target pathways that are 
quantitative altered in cancer cells. Nonetheless, these pathways, as previously 
discussed, are also present in normal cells, and so, these molecules fail to be a 
truly targeted therapy. 
 A study (65) showed a promising approach to TNBC androgen receptor 
(AR) positive subtype. It shows that administrating AR agonists on the malignant 
cells, revealed a 50% bigger growth inhibition effect compared to placebo. 
However, AR is not exclusively expressed in BC, it’s also present in other tissues, 
such as: ovary, uterus and fallopian tubes (66), demonstrating the lack of 
selectivity in the current small-molecules targeting ability.  
 Many more studies and reviews(67–78), report promising small-molecules 
discovered, with different targeting strategies. However, there’s always a lack of 
selectivity, because they only target an overexpressed pathway or receptor, not 





 A study stood out from the others, regarding selectivity in targeting 
malignant cells (79). It explains that carbonic anhydrase IX (CAIX) might be vital 
to the metastasis progression, and that it plays an important role in tumour 
survival on hypoxic conditions, through the regulation of the cell’s pH. CAIX is a 
membrane-bound enzyme that reversibly catalyses the hydration of CO2, 
exclusively expressed on hypoxic tumours, including some forms of BC. This 
enzyme has been targeted with sulphonamide-based imaging probes and 
antibodies (80,81). Due to its selectivity, CAIX could also become an interesting 
target to the development of drug-delivery strategies. There are already some 
inhibitors, derivates of acetazolamide, that show tumour growth inhibition but lack 
specificity for CAIX. Another inhibitor reported in a different paper (82) is CAI17, 
described as a highly selective sulphonamide-based inhibitor. CAI17 inhibitor 
acts as a prodrug and the strategy behind its development relies on the disulphide 
bond that will be further reduced due to the hypoxic conditions and the presence 
of thioredoxin 1 protein, forming a thiol group.  
 This discovery can also lead to novel tumour elimination strategies, as new 
drugs could locally force a hypoxic state in the malignant cells, allowing the 
endogenous expression of CAIX to be further targeted.  
Another inhibitor, EZN-2968, a synthetic locked nucleic acid antisense 
oligodeoxynucleotides is being developed to target (hypoxia-inducible factor) 
HIF-1α (83). HIF-1 is a heterodimeric transcription factor activated in hypoxic 
conditions to maintain tumour survival and progression. It consists of two 
Figure 5 - Molecular structure of CAIX inhibitor CAI17. Adapted from Lou Y, McDonald PC, Oloumi A, 
Chia S, Ostlund C, Ahmadi A, et al. Targeting Tumour Hypoxia: Suppression of Breast Tumour 




subunits, HIF-1α and HIF-1β. Only the HIF-1α subunit expression is oxygen 
sensitive, while HIF-1β expression is uniquely concomitant. Despite also being 
expressed in normal cells, HIF-1α undergoes a rapid degradation process, having 
a half-life of only 5 minutes. However, under hypoxic conditions, it can be 
stabilized through several pathways for longer periods. HIF-1α also regulates 
CAIX expression levels (84). HIF-1α represents a promising target regarding 
broad cancer selectivity (85).  
 As analysed, very few small-molecules have promising approaches to 
efficiently target BC cells. However, they have clinical potential as single targets, 
and can be proven useful when further conjugated with another molecule 
responsible for selectively delivering the drug. 
Monoclonal Antibodies 
 Monoclonal antibodies (mAb) are glycoproteins belonging to the 
immunoglobin superfamily endogenously produced by B cells. They are γ-
shaped, consisting of two chains: the heavy and the light chain. The heavy chain, 
has three constant regions and one variable region, while the light chain has one 
constant region and one variable region. Both variable regions form the antigen-
binding fragment and when presented with an antigen they will bound exclusively 
to it, due to six peptide loops known as the complementarity-determining regions 
(CDR) (86,87). Manipulating the CDR has a great therapeutic value, since this 
region binds selectively with the complementary antigen, allowing novel drugs to 
be more efficient. This is the main reason why, after the release of the first mAb 
to the market, there’s still an ongoing growth of its production (88). 
 mAb are high molecular weight proteins (usually about 150 kDa), and very 
water soluble. Such characteristics make them ideally stable in the vascular 
compartment, with very small percentage found in the extracellular fluid. 
Administration routes as sub-cutaneous or intra-muscular are not eligible due to 
their proprieties. Thanks to their high weight, filtration through the glomerulus 
does not occur, increasing its serum half-life, sometimes reaching 21 days. They 
reach the extracellular compartment due to extravasation, endocytosis or 




bind through the CDR region and suffer cellular internalization followed by 
proteolysis, due to the lysosomal vesicles present within the cell (89). 
 These proprieties make antibodies a promising drug in targeting BC, 
despite failing at local-region administration. 
 Ganitumab, cixutumumab, dalotuzumab and OSI-906 are mAb, used in 
metastatic BC, designed to target insulin-like growth factor-1 receptor (IGF-1R). 
This receptor is implicated in cell growth pathways, of both normal and malignant 
cells. MEDI-573 and BI836845 act by binding to the IGF I and II, and not the 
receptor (64,90–92). 
 Other mAb such as bevacizumab were developed to target VEGF (93). 
Vascular endothelial growth factor, is a protein that increases blood vessels 
production. However, it’s not its only role, it’s also important in bone formation, 
wound healing and haematopoiesis, and so, it’s not exclusive of malignant cells 
(94). 
 Yet again, despite the significant clinical value in BC, these antibodies fail 
to be a selective approach to treat BC, since they can’t distinguish normal cells. 
 The pharmaceutical companies test their patent mAbs in different cancers 
to target cell-broad pathways, so they can additionally prove its value on another 
cancer type to increase their total drug market value. However, even with 
successful clinical value, these mAbs will not bring a targeted approach. 
Nanoparticles 
 Nanoparticles are compounds with an average range of 1 to 1000 nm (10-
9 m). When used clinically they must achieve a closer range of 10 to 200 nm. This 
limitation is set due to two conditions. The smaller value accounts for the 5 nm 
renal filtration cut-off, increasing the drug’s blood half-life and eventually 
increasing its efficiency. The bigger value accounts for the standard 220 nm filter 
used in theranostic applications. Theranostic is a term describing the diagnostic 
and therapeutic proprieties of the same drug, that advance nanoparticles present. 
Usually nanoparticle drugs may contain one or more of the following: liposomes, 
micelles, polymers, dendrimers and/or macromolecules (95,96). Nanoparticles 




(EPR) effect on tumour cells, compared with other drug classes. The EPR effect 
is a phenomenon occurring in the vascular tissue around a solid tumour. Due to 
the tumour-induced angiogenesis surrounding blood vessels, there’s a gap in the 
junction of the endothelial cells and, additionally, a lack of smooth muscle layers. 
This creates large fenestrations that allow drugs to leave the circulatory system 
and deposit on the tumour cells. Additionally, overexpression of vascular 
mediators such as nitric oxide, bradykicin, etc. enhances the permeability of these 
vessels (97). This effect grants additional selectivity compared with the previous 
discussed drug classes. To design nanoparticles, understanding its 
pharmacokinetics and pharmacodynamics is critical.  Factors like PEGylation, 
size, composition, zeta potential, and shape, will determine its clearance due to 
its opsonization with macrophages on the liver and spleen (96).  
 The PEGylation steps consist of using polyethylene glycol (PEG) in the 
surface of these drugs to reduce serum protein binding through steric hindrance. 
Although it has its relevance in drug deliver optimization, it also induces immune 
response and hypersensitivity, remaining its use unclear, and making necessary 
a benefit/risk analysis (96). 
 Another concept to keep in mind is ligand addition. A study compared the 
penetration ability of two micelles, one with ligands of the surface and another 
without them. Surprisingly, the micelles without the surface ligand showed better 
penetration. This effect is described as the binding site barrier, that difficults 
nanoparticle internalization (96). 
Figure 6 - EPR effect. The endothelium cells in the blood vessels near the malignant 




 Regarding BC targeting, one study (98) developed a curcumin lipid-base 
nanoparticle. It reports that curcumin, a yellow pigment, has anti-oxidant and anti-
tumour proprieties, implicated in several cell mechanisms. However, a 
nanoparticle system had to be designed due to its poor stability on physiological 
conditions. To increase its targeting value, folate was added as a surface ligand, 
because many solid tumours have an increased expression of folate receptors. 
According to the results, this nanoparticle showed promising tumour growth 
inhibition, and reduced toxicity.  
Folate receptors are reported to be great markers for targeting cancer in 
IV strategies, since they can be selective in targeting malignant cells. Normal 
cells express the folate receptor on the apical membrane surface of polarized 
epithelial cells, away from the blood circulation, preventing interaction with folate-
mediated drugs. Upon malignant transformation, they lose its polarity and the 
folate receptor becomes available to the blood circulation, being ready to react 
with folate (99). However, a pregnant woman’s breast cells also release folate to 
the milk in order to feed the embryo (100). Usage of folate to selective distinguish 
malignant cells requires a patient filtration to deliver an effective drug. 
 Other results found (101–106), share the selective targeting issue, due to 
the  use of ligands that won’t distinguish normal from malignant cells. However, 
their design strategies are different and interesting for discussion.  
 One group, developed a multifunctional magnetic polymer nanoparticle 
with “switchable On-Off” states. This nanoparticle acts accordingly to the 
environmental pH. On the blood the core stays intact, but when internalized to 
the cell, the acidic pH disintegrates the nanoparticle, allowing a release of the 
desirable drug. This effect was achievable through the use of hydrophobic 
polymer, D,L-lactic-co-glycolic acid (PLGA). This strategy largely increases drug 
stability in blood circulation (102).  
 Another nanoparticle design used mesoporous silica with fluorescein 
isothiocyanate (FITC) in the internal surface, conjugated with the HER2 mAb. The 
use of FITC-labelling antibodies allows imaging detection upon CDR binding to 
the antigen, through the emission of green florescence. The emission is granted 




mesoporous silica nanoparticles also allow a tailor design due to their controlled 
pore size and surface functionalization (103). 
 Another study (106), developed a slightly different nanoparticle. While the 
others had a core-like or porous-like structure, this study developed a biomimetic 
vector, with a rod-like structure. It contained: plasmid DNA, nuclear localisation 
signal, a DNA condensing motif, an endosomal disruptive motif, a cathepsin 
substrate and a cyclic targeting peptide, CPX (108). This fragmentation allows 
the condensation of the DNA to the nano-scale, protection from serum 
endonucleases, disruption of endosomal membranes and selective cell targeting. 
Interestingly, the targeted peptide showed selectivity to a specific BC cell line and 
not to a normal breast cell line. However, clinical practice has demonstrated that 
BC demands broader strategies to be developed to deliver an efficient therapy. 
 Two studies used gold nanoparticles (104,105). These compounds are 
widely explored in biomedicine applications. They have excellent compatibility 
with the physiological conditions, demanded by the cells, low toxicity, and can 
interact with a great variety of substances (109). One study found an interesting 
approach to treat cancer, using photothermal laser on the gold nanoparticles. 
Upon internalization of the gold nanoparticles, further near-infrared light is used 
to trigger the cells to enter hyperthermia, leading to cell death. The study showed 
that the amount of killed cells can be controlled by the exposure time and power 
density of the light. Additionally, cells that did not internalized gold nanoparticles, 
when submitted to the same treatment, maintained their integrity (104). This 
strategy can grant a precise and selective method to the treat BC, with the 
addition of a conjugated fluorescence probe and with real-time imaging 
technology, allowing the selection and destruction in real-time of each malignant 
cell.  
 As seen, the design of nanoparticles is complex with many different cores, 
layers and layouts able to integrate a variety of substances. Although 
nanoparticles are more complex drugs than small molecules or mAb, the 
selection of an appropriate selective target still is the critical step in delivering 
successful therapies. However, due to their EPR effect, they’re additionally more 





 Bioconjugation is a branch in chemistry that studies the ability to link two 
functional molecules through a stable inert linker, that usually forms covalent 
bounds with the molecules. It can also have theranostics proprieties, depending 
on the nature and intent of the molecules used. As previously mentioned it can 
be used in the design of nanoparticles. However, in this drug class, only non-
nanoparticle therapies will be discussed.  
 A group of conjugates that are gaining importance are antibody-drug 
conjugates (ADC). This drug class consists on the binding of a mAb to a cytotoxic 
drug via a stable linker. Through binding both molecules, the conjugate surpasses 
each ones’ limitations while preserving their benefits. Another component, crucial 
to the design of ADC is the linker. The linker must be stable at physiological 
conditions, only releasing the drug when presented with a previous defined target, 
such as acidic pH or specific proteases. However, if the linker is not stable it can 
release the drug earlier than expected and increase drug toxicity (110).   
 One ADC design to BC is Trastuzumab-DM1 (111). DM1 is a 
maytansinoids derivative of the drug maytansine. It acts by binding with the 
microtubules inhibiting the mitosis process. The initial linker used consists of 
disulphide bridges, however, linker cleavage was reported as inefficient. When 
the linker changed to a thioether bridge, it showed increase efficiency. In vivo 
studies also confirmed the increased growth inhibition of the ADC compared with 
the mAb or the small drug alone, promising a better alternative to standard 
trastuzumab alone therapy.  
 
Figure 7 -Trastuzumab-DM1 structure scheme. Adapted from Lewis Phillip GD, Li G, Dugger DL, 
Crocker LM, Parsons KL, Mai E, et al. Targeting HER2-positive Breast Cancer with trastuzumab-




Another ADC design used FITC-labelled trastuzumab-grafted G4 PAMAM 
[poly(amido)amine] dendrimers. Through the terminal amine of PAMAM, five 
FITC molecules were bond. To link the mAB, a PEG-Maleimide spacer was used. 
After reacting a trastuzumab’s amine with the straut’s reagent, the mAb was 
ready to be linked to the FITC-PAMAM-PEG-MAL structure, forming a complex 
conjugate. The dendrimers were previously loaded with docetaxel. In vitro 
fluorescent microscopy, showed a great growth inhibition effect of the conjugate, 
compared with dendrimer-loaded docetaxel without trastuzumab, and greater 
than docetaxel alone. Docetaxel plasma concentrations were also greatly 
increased with the use of the conjugated compared with docetaxel alone (112).   
 As the HER2 receptor is only overexpressed and not selectively expressed 
in BC, this strategies lack selective proprieties. 
 However, an interesting study design a conjugate that can distinguish high 
HER2 expression levels from low levels (113). This study, aims to target STAT3 
(signal transducer and activators of transcription 3), which is suspected to induce 
Erb2 transformation and tumour progression on Erb2 overexpressed BC cells. To 
selective target these cells, some CPP (cell-penetrating peptides) showed 
promising results due to its effectiveness of crossing cell membranes and deliver 
bioactive cargos. One of those examples is the transduction and transactivation 
(TAT) protein of HIV. Using TAT derivatives conjugated with an anti-HER-2/neu 
peptide mimetic (AHNP) promises to be a great a selective delivery system that 
will further incorporate STAT3BP, known to inhibit STAT3 signalling. The results, 
showed a selective internalization of the TAT-AHNP-STAT3BP to BC cell lines 
with an overexpression of HER-2, compared with cell lines with basal HER-2 
expression levels. Additionally, it showed that in vivo results, where HER-2 
overexpressed mouse had a greater apoptosis effect, with designed drug, 
compared with a HER-2 cell line with normal expression levels. This strategy is 
one of the effective BC target therapies due to its targeting ability described in 
this study. However, only 30% of the BC subtypes are HER-2 positive, 
demanding novel strategies to treat other BC subtypes. 
  Another study using CPP promises a novel strategy selectively targeting 
BC cells (114). The designed has: 1) SP90, a 12 amino-acid tumour homing 




acid CPP derived from the heparin-binding domain of superoxide dismutase, 3) 
a Viral Protein R, a small apoptotic protein and 4) a green fluorescence protein. 
Although this study lacks in vivo report, it showed BC selectivity towards 
ER+/PR+/HER2- and triple-negative cell-lines, compared with normal breast cell 
and other cancer cell lines. Additionally, it showed that only the full drug 
presented cell internalization, while other incomplete parts failed to either be 
selective or internalized. Despite the targeting ability of SP90, there’s no 
information about its molecular binding target. 
 These studies demonstrate the clinical value of drug designs containing 
CPP to selectively internalize drugs on BC cells, and can even be a promising 
approach to treat triple-negative cell line, which has the worst prognosis. 
Future Perspectives 
 As reviewed, BC is a dangerously disease, affecting mostly women world-
wide. It’s heterogenous, with many different phenotypes, being almost each case 
unique. Regarding current chemotherapy, it only acts as adjuvant, allowing a 
reduction of the growth and size of the tumour, so it could be further removed 
through a surgical procedure. Additionally, current therapy can’t distinguish 
normal cells from malignant cells, causes adverse effects on the patient, leads to 
a painful therapy, causing some people to abandon it. In some advance forms of 
BC (metastasis), the drug therapy only allows an extension of the patient’s life, 
usually few months.  
 There’s a demand in finding a solution to treat BC. One without side effects 
and not invasive to the patient. To manage such achievement, as discussed, 
many researchers are developing novel approaches, to selectively target BC 
using drugs. However, only few prove to be an effective approach, because many 
did not have an unique target to deliver drugs selectively onto BC cells.  
 An interesting approach, is targeting either HIF-1α or CAIX, since they’re 
both selective markers expressed only when cells suffer hypoxia (84,115). 
Instead of neutralizing these proteins activity in cell survival, they should be kept 
expressed to design selective strategies. Regarding HIF-1α, one hypothesis is to 




47ºC cells start to express HIF-1α, through ERK and ARK pathways on lung 
cancer cell lines (116). Initially, BC cells would be exposed to the heat through a 
targeted approach, and next, an ADC could be designed, whereas the mAb would 
be developed to target the HIF-1α and, linked to it, a drug reported to induce 
apoptosis on BC cells. 
  Another great strategy discussed was the use of folate as a selective 
ligand to target BC cells. Further investigating folate receptor expression, a study 
(117) compared the expression levels on both normal and malignant breast cell 
lines, as well as folate expression on other normal and malignant cells on different 
organs. As reported, larger expression was found in malignant breast cells, 
however, not in a selective amount from normal cells. Additionally, IV 
administration therapies would fail to be selective because lung and kidney 
normal cells lines express equal or bigger amounts of the folate receptor. The 
folate targeting strategy remains inconclusive, as different studies suggests 
different theories.  
 CPP also proved to be an efficient approach on selective internalizing onto 
BC, when attached with a homing protein. Their internalization is supposed to 
occur through the electrostatic affinity of the CPP positive charges to the 
negatively charged proteoglycans and phospholipids on cell surface. To design 
these peptides, it’s important to attribute the right charge and hydrophobic 
proprieties, because it will decide if the peptide can enter the cell. This study (118) 
mentioned the importance of arginine residues on the CPP rather than lysine. 
This residue change is due to the interaction of arginine to the cell surface being 
greater than with the lysine group. The guanidinium group of arginine forms 
bidentate hydrogen bonds with the negatively charged phosphate, sulphate and 
carboxylate groups on cell surface, while lysine only forms one hydrogen bond.  
Hydrophobicity also plays an important role as it is crucial to enter the cell 
lipid bilayer.  Among hydrophobic residues, aromatic groups can evenly help both 
hydrophobic and charged proprieties of the CPP. Tryptophan was proved to be 
an efficient residue regarding cellular uptake. Plus, tryptophan, as arginine, can 
interact with sugar rings on cell surface. Additionally, tryptophan residues, when 
near to arginine residues, changes the later pKa of the guanidinium group to a 




Table 3 – Studied cell-penetrating peptides and their respective sequence’s. Adapted from Bechara C, 
Sagan S. Cell-penetrating peptides: 20 years later, where do we stand? 
Peptide Sequence 
Protein derived  
Penetratin RQIKIWFQNRRMKWKK 











 Ultimately conjugating CPP with the previously designed gold nanocages 
that, when targeted by near-infrared light causes cell death, seems an effective 
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Table 4 – Breast Cancer Classification. Adapted from Breast Cancer Staging: TNM Classification for 
Breast Cancer 
Primary Tumour (T) 
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
Tis Carcinoma in situ 
Tis (DCIS) Ductal carcinoma in situ 
Tis (LCIS) Lobular carcinoma in situ 
Tis (Paget) Paget disease of the nipple NOT associated with 
invasive carcinoma and/or carcinoma in situ (DCIS 
and/or LCIS) in the underlying breast parenchyma. 
Carcinomas in the breast parenchyma associated with 
Paget disease are categorized based on the size and 
characteristics of the parenchymal disease, although the 
presence of Paget disease should still be noted 
T1 Tumor ≤ 20 mm in greatest dimension 
T1mi Tumor ≤ 1 mm in greatest dimension 
T1a Tumor > 1 mm but ≤ 5 mm in greatest dimension 
T1b Tumor > 5 mm but ≤ 10 mm in greatest dimension 
T1c Tumor > 10 mm but ≤ 20 mm in greatest dimension 
T2 Tumor > 20 mm but ≤ 50 mm in greatest dimension 
T3 Tumor > 50 mm in greatest dimension 
T4 Tumor of any size with direct extension to the chest wall 
and/or to the skin (ulceration or skin nodules) 
T4a Extension to chest wall, not including only pectoralis 
muscle adherence/invasion 
T4b Ulceration and/or ipsilateral satellite nodules and/or 
edema (including peau d’orange) of the skin, which do 
not meet the criteria for inflammatory carcinoma 
T4c Both T4a and T4b 
T4d Inflammatory carcinoma 
Regional Lymph Nodes (N) 
Clinical 
NX Regional lymph nodes cannot be assessed (eg,previously 
removed) 




N1 Metastasis to movable ipsilateral level I, II axillary lymph 
node(s) 
N2 Metastases in ipsilateral level I, II axillary lymph nodes 
that are clinically fixed or matted or in clinically detected* 
ipsilateral internal mammary nodes in the absence of 
clinically evident axillary lymph node metastasis 
N2a Metastases in ipsilateral level I, II axillary lymph nodes 
fixed to one another (matted) or to other structures 
N2b Metastases only in clinically detected* ipsilateral internal 
mammary nodes and in the absence of clinically evident 
level I, II axillary lymph node metastases 
N3 Metastases in ipsilateral infraclavicular (level III axillary) 
lymph node(s), with or without level I, II axillary node 
involvement, or in clinically detected * ipsilateral internal 
mammary lymph node(s) and in the presence of clinically 
evident level I, II axillary lymph node metastasis; or 
metastasis in ipsilateral supraclavicular lymph node(s), 
with or without axillary or internal mammary lymph node 
involvement 
N3a Metastasis in ipsilateral infraclavicular lymph node(s) 
N3b Metastasis in ipsilateral internal mammary lymph node(s) 
and axillary lymph node(s) 
N3c Metastasis in ipsilateral supraclavicular lymph node(s) 
Pathologic (pN) 
pNX Regional lymph nodes cannot be assessed (for example, 
previously removed, or not removed for pathologic study) 
pN0 No regional lymph node metastasis identified 
histologically. Note: Isolated tumor cell clusters (ITCs) 
are defined as small clusters of cells ≤ 0.2 mm, or single 
tumor cells, or a cluster of < 200 cells in a single 
histologic cross-section; ITCs may be detected by 
routine histology or by immunohistochemical (IHC) 
methods; nodes containing only ITCs are excluded from 
the total positive node count for purposes of N 
classification but should be included in the total number 
of nodes evaluated 
pN0(i-) No regional lymph node metastases histologically, 
negative IHC 
pN0(i+) Malignant cells in regional lymph node(s) ≤ 0.2 mm 
(detected by hematoxylin-eosin [H&E] stain or IHC, 
including ITC) 
pN0(mol-) No regional lymph node metastases histologically, 




polymerase chain reaction [RT-PCR]) 
pN0(mol+) Positive molecular findings (RT-PCR) but no regional 
lymph node metastases detected by histology or IHC 
pN1 Micrometastases; or metastases in 1-3 axillary lymph 
nodes and/or in internal mammary nodes, with 
metastases detected by sentinel lymph node biopsy but 
not clinically detected 
pN1mi Micrometastases (> 0.2 mm and/or > 200 cells, but none 
> 2.0 mm) 
pN1a Metastases in 1-3 axillary lymph nodes (at least 1 
metastasis > 2.0 mm) 
pN1b Metastases in internal mammary nodes, with 
micrometastases or macrometastases detected by 
sentinel lymph node biopsy but not clinically detected 
pN1c Metastases in 1-3 axillary lymph nodes and in internal 
mammary lymph nodes, with micrometastases or 
macrometastases detected by sentinel lymph node 
biopsy but not clinically detected 
pN2 Metastases in 4-9 axillary lymph nodes or in clinically 
detected internal mammary lymph nodes in the 
absence of axillary lymph node metastases 
pN2a Metastases in 4-9 axillary lymph nodes (at least 1 tumor 
deposit > 2.0 mm) 
pN2b Metastases in clinically detected internal mammary 
lymph nodes in the absence of axillary lymph node 
metastases 
pN3 Metastases in ≥ 10 axillary lymph nodes; or in 
infraclavicular (level III axillary) lymph nodes; or in 
clinically detected ipsilateral internal mammary lymph 
nodes in the presence of ≥ 1 positive level I, II axillary 
lymph nodes; or in > 3 axillary lymph nodes and in 
internal mammary lymph nodes, with micrometastases or 
macrometastases detected by sentinel lymph node 
biopsy but not clinically detected; or in ipsilateral 
supraclavicular lymph nodes 
pN3a Metastases in ≥ 10 axillary lymph nodes (at least 1 tumor 
deposit > 2.0 mm); or metastases to the infraclavicular 
(level III axillary lymph) nodes 
pN3b Metastases in clinically detected ipsilateral internal 
mammary lymph nodes in the presence of ≥ 1 positive 
axillary lymph nodes; or in > 3 axillary lymph nodes and 
in internal mammary lymph nodes, with micrometastases 




biopsy but not clinically detected 
pN3c Metastases in ipsilateral supraclavicular lymph nodes 
Distant Metastasis (M) 
M0 No clinical or radiographic evidence of distant metastasis 
cM0(i+) No clinical or radiographic evidence of distant 
metastases, but deposits of molecularly or 
microscopically detected tumor cells in circulating blood, 
bone marrow, or other nonregional nodal tissue that are 
no larger than 0.2 mm in a patient without symptoms or 
signs of metastases 
M1 Distant detectable metastases as determined by classic 
clinical and radiographic means and/or histologically 
proven > 0.2 mm 
 
Table 5 – Breast Cancer Stages. Adapted from Breast Cancer Staging: TNM Classification for Breast 
Cancer 
STAGE T N M 
0 Tis N0 M0 
IA T1 N0 M0 
IB T0 N1mi M0 
 T1 N1mi M0 
IIA T0 N1 M0 
 T1 N1 M0 
 T2 N0 M0 
IIB T2 N1 M0 
 T3 N0 M0 
IIIA T0 N2 M0 
 T1 N2 M0 
 T2 N2 M0 
 T3 N1 M0 
 T3 N2 M0 
IIIB T4 N0 M0 
 T4 N1 M0 
 T4 N2 M0 
IIIC Any T N3 M0 




Table 6 - Amino Acid three letters and one letter codes. 
Amino Acid Code Designation 
Amino acid Three Letter Code  One Letter Code 
Alanine Ala A 
Arginine Arg R 
Asparagine Asn N 
Aspartic Acid Asp D 
Cysteine Cys C 
Glutamine Gln Q 
Glutamic Acid Glu E 
Glycine Gly G 
Histidine His H 
Isoleucine Ile I 
Leucine Leu L 
Lysine Lys K 
Methionine Met M 
Phenylalanine Phe F 
Proline Pro P 
Serine Ser S 
Threonine Thr T 
Tryptophan Trp W 
Tyrosine Tyr Y 






Conjugated gold nanoparticles synthesis scheme (119,120) 
 
 
